BDNF

Cognitive Function and Memory

BDNF is required for hippocampal LTP, the cellular mechanism of learning and memory. Korte et al. (1995) showed that BDNF knockout mice have severely impaired LTP in hippocampal CA1, which is rescued by exogenous BDNF application. BDNF promotes dendritic spine growth, increases AMPA receptor insertion at synapses, and enhances the late phase of LTP through CREB-dependent gene transcription.

In humans, serum BDNF levels correlate positively with hippocampal volume, episodic memory performance, and processing speed. Val66Met carriers (approximately 20-30% of European and 40-50% of Asian populations) have reduced hippocampal volume, impaired episodic memory, and altered prefrontal cortical function on neuroimaging.

Exercise-Induced BDNF

Exercise is the most potent known inducer of peripheral and central BDNF expression. Acute aerobic exercise increases circulating BDNF by 2-3 fold, with the effect proportional to exercise intensity. Wrann et al. (2013) identified the molecular mechanism: exercise activates PGC-1alpha in skeletal muscle, which induces FNDC5 (irisin precursor). Irisin crosses the blood-brain barrier and stimulates hippocampal BDNF gene expression through ERK-CREB signaling. This muscle-brain endocrine axis explains how peripheral exercise produces central neuroplastic effects.

Sleiman et al. (2016) demonstrated that exercise-induced lactate also crosses the BBB and activates SIRT1-dependent deacetylation of BDNF promoter regions, providing a second exercise-BDNF signaling pathway. Regular exercise training elevates baseline BDNF levels and enhances activity-dependent BDNF secretion.

Neurodegeneration

BDNF levels are reduced in Alzheimer's disease (AD) hippocampus, Parkinson's disease substantia nigra, and Huntington's disease striatum. In AD, amyloid-beta oligomers directly impair BDNF-TrkB signaling by promoting TrkB dephosphorylation and internalization, and by upregulating truncated TrkB-T1. Peng et al. (2005) showed that BDNF delivery reverses synapse loss and improves memory in AD mouse models, but BDNF cannot cross the blood-brain barrier, limiting direct therapeutic application.

In Huntington's disease, mutant huntingtin protein reduces BDNF transcription by sequestering the transcriptional repressor REST/NRSF in the cytoplasm in wild-type cells but failing to do so when mutated. Zuccato et al. (2001) identified this mechanism, showing that cortical BDNF transport to the striatum is reduced in HD, contributing to striatal neurodegeneration.

Depression and Antidepressant Mechanisms

The BDNF hypothesis of depression emerged from observations that stress decreases hippocampal BDNF levels, that chronic antidepressant treatment increases BDNF expression, and that direct BDNF infusion into the hippocampus produces antidepressant-like effects in rodents. Duman & Monteggia (2006) formulated the neurotrophic hypothesis of depression, proposing that reduced BDNF-TrkB signaling in hippocampus and PFC underlies stress-related neuronal atrophy and that antidepressants work by restoring this signaling.

Ketamine's rapid antidepressant effect is mediated through BDNF-TrkB signaling. Autry et al. (2011) showed that ketamine blocks tonic NMDA receptor activity on GABAergic interneurons, disinhibiting glutamatergic neurons, triggering rapid BDNF release and TrkB activation that drives mTOR-dependent synaptogenesis within hours. BDNF conditional knockout mice do not respond to ketamine, establishing BDNF as an essential mediator.

Castrén & Monteggia (2021) reviewed how virtually all antidepressant treatments — SSRIs, SNRIs, ketamine, electroconvulsive therapy, exercise, and psychedelics — converge on BDNF-TrkB signaling to promote neuroplasticity, proposing that antidepressants open a "critical period" of plasticity rather than directly altering mood.

Peptide Mimetics and Small Molecule TrkB Agonists

Because BDNF itself has poor drug-like properties, significant effort has focused on developing TrkB agonists:

7,8-Dihydroxyflavone (7,8-DHF): A naturally occurring flavonoid identified as a selective TrkB agonist (EC50 ~10-100 nM) that mimics BDNF effects. Jang et al. (2010) showed that 7,8-DHF binds the TrkB extracellular domain, promotes TrkB dimerization and autophosphorylation, activates downstream ERK and AKT pathways, and is orally bioavailable and BBB-permeable. It has shown antidepressant, neuroprotective, and memory-enhancing effects in multiple preclinical models.

LM22A-4: A small molecule TrkB partial agonist (EC50 ~200-700 nM) designed through in silico screening of BDNF loop domains. Massa et al. (2010) showed it promotes TrkB activation, neuronal survival, and functional recovery after traumatic brain injury.

BDNF loop peptides: Short peptide mimetics derived from BDNF loop regions (loops 1-4) that interact with TrkB. Cyclic peptide mimetics of BDNF loop 2 show selective TrkB activation in vitro.

Neuroplasticity and mood

BDNF acting via TrkB drives activity-dependent synaptic plasticity; the neurotrophic hypothesis of depression positions BDNF as both a mediator and biomarker of antidepressant and exercise responses.

• Peripheral BDNF increases acutely with high-intensity exercise and chronically with antidepressants
• Val66Met polymorphism alters activity-dependent BDNF secretion and treatment response

Therapeutic delivery challenges

Direct recombinant BDNF has poor pharmacokinetics and blood-brain-barrier penetration; ALS trials failed on efficacy despite biological rationale, shifting the field toward TrkB small-molecule agonists and gene/cell delivery.

• Systemic and intrathecal rhBDNF trials in ALS did not meet endpoints
• Short half-life and receptor desensitization limit exogenous BDNF as a drug